Poly ADP-Ribose Polymerase (PARP) Inhibitor Global Market Report 2024

Description

Poly ADP-ribose polymerase (PARP) inhibitors are a category of pharmacological agents that function by inhibiting the enzyme PARP, crucial for DNA repair processes. By blocking PARP, these inhibitors effectively target cancers with deficiencies in other DNA repair pathways, thereby preventing cancer cells from repairing damaged DNA and ultimately leading to their demise.

The primary drug types of PARP inhibitors include talazoparib, veliparib, olaparib, and others. Talazoparib, for instance, is a potent PARP inhibitor utilized in cancer therapy, disrupting DNA repair mechanisms within cancer cells. These drugs are distributed through various channels such as hospital pharmacies, online pharmacies, retail pharmacies, among others. They have demonstrated efficacy in treating ovarian cancer, breast cancer, and other malignancies, and are utilized by various end users including hospitals, homecare facilities, specialty clinics, and others.

The poly ADP-ribose polymerase (PARP) inhibitor market research report is one of a series of new reports from The Business Research Company that provides poly ADP-ribose polymerase (PARP) inhibitor market statistics, including poly ADP-ribose polymerase (PARP) inhibitor industry global market size, regional shares, competitors with a poly ADP-ribose polymerase (PARP) inhibitor market share, detailed poly ADP-ribose polymerase (PARP) inhibitor market segments, market trends and opportunities, and any further data you may need to thrive in the poly ADP-ribose polymerase (PARP) inhibitor industry. This poly ADP-ribose polymerase (PARP) inhibitor market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The poly ADP-ribose polymerase (PARP) inhibitor market size has grown rapidly in recent years. It will grow from7.52 billion in 2023 to $8.39 billion in 2024 at a compound annual growth rate (CAGR) of 11.6%. The growth observed in the historical period can be attributed to several factors, including increased investment in clinical research, regulatory approvals for new drugs, intensified market competition among pharmaceutical companies, the development of drug combinations for enhanced efficacy, and the advocacy efforts of patients and patient advocacy groups.

The poly ADP-ribose polymerase (PARP) inhibitor market size is expected to see rapid growth in the next few years. It will grow to $13.13 billion in 2028 at a compound annual growth rate (CAGR) of 11.8%. The forecast period's growth is expected to be fueled by factors such as expanded indications for treatments, the advancement of personalized medicine approaches, the development of biomarkers, considerations in health economics, and the increasing penetration into emerging markets. Key trends anticipated in the forecast period encompass the rise of precision medicine initiatives, advancements in immunotherapy, the development of targeted therapies, the integration of artificial intelligence into drug discovery processes, and the adoption of patient-centric healthcare models.

The uptick in ovarian cancer cases is anticipated to be a driving force behind the expansion of the poly ADP-ribose polymerase (PARP) inhibitor market. Ovarian cancer, a malignancy affecting one or both ovaries, is influenced by factors such as genetic predisposition, aging demographics, environmental exposures, and hormonal imbalances. Poly ADP-Ribose Polymerase (PARP) Inhibitors serve as a vital component in ovarian cancer therapy, targeting DNA repair mechanisms, especially in patients harboring BRCA mutations, thereby inducing synthetic lethality and augmenting tumor cell demise. For instance, data from the World Ovarian Cancer Coalition in February 2022 revealed that ovarian cancer affected 3.13 million women globally in 2020, with projections indicating a 42% surge to reach 4.4 million by 2040. Furthermore, ovarian cancer-related deaths are anticipated to climb by 51% over the same period, rising from 2.07 million in 2020 to 3.13 million in 2040. Consequently, the escalating prevalence of ovarian cancer acts as a catalyst for the growth of the poly ADP-ribose polymerase (PARP) inhibitor market.

Leading players in the poly ADP-ribose polymerase (PARP) inhibitor market are focusing on the development of generic PARP inhibitors, tailored to cater to cancer patients with specific genetic mutations, thus offering personalized treatment modalities. Generic PARP inhibitors function by inhibiting the activity of the enzyme poly ADP-ribose polymerase (PARP). For example, Zydus Lifesciences Limited, an India-based pharmaceutical company, launched Olaparib under the IBYRA brand in March 2024. This PARP inhibitor targets specific genetic mutations prevalent in breast, ovarian, prostate, and pancreatic cancers, providing a customized and efficacious treatment regimen. Particularly advantageous for patients with HRD-positive or BRACA mutations, Olaparib aids in postponing disease progression, thereby enhancing patient outcomes.

In June 2023, Ariceum Therapeutics GmbH, a Germany-based radiopharmaceutical company, acquired Theragnostics Ltd. for $41.5 million. This strategic acquisition bolstered Ariceum Therapeutics' radiopharmaceutical portfolio, granting access to novel PARP inhibitor radiation therapies. Theragnostics Ltd., a UK-based biotechnology company, specializes in the development of radio-labeled PARP inhibitors for both diagnostic and therapeutic applications in tumor management.

Major companies operating in the Poly ADP-ribose polymerase (PARP) inhibitor market are Pfizer Inc., Johnson & Johnson Services Inc., AbbVie Inc., Bayer AG, Novartis AG, Sanofi S.A., AstraZeneca plc, GlaxoSmithKline plc., Takeda Pharmaceutical Company Limited, Merck KGaA, Teva Pharmaceutical Industries Ltd., Daiichi Sankyo Company Limited, Eisai Co. Ltd., Ipsen Biopharmaceuticals Inc., Genentech Inc., BioMarin Pharmaceutical Inc., Seattle Genetics Inc., Medivation Inc., Myriad Genetics Inc., PharmaMar S.A., Clovis Oncology, Nektar Therapeutics, Loxo Oncology Inc., Tolero Pharmaceuticals Inc., Everest Pharmaceuticals, Verastem Inc.

North America was the largest region in the poly ADP-ribose polymerase (PARP) inhibitor market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the Poly ADP-ribose polymerase (PARP) inhibitor market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the Poly ADP-ribose polymerase (PARP) inhibitor market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The poly ADP-ribose polymerase (PARP) inhibitor market consists of revenues earned by entities by providing services such as diagnostic tests, clinical trials, consulting services, and patient support programs. The market value includes the value of related goods sold by the service provider or included within the service offering. The poly ADP-ribose polymerase (PARP) inhibitor market also includes sales of test kits, laboratory equipment, imaging systems, sample processing instruments, reagents, and chemicals. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Poly ADP-Ribose Polymerase (PARP) Inhibitor Global Market Report 2024 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on poly adp-ribose polymerase (PARP) inhibitor market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Gain a truly global perspective with the most comprehensive report available on this market covering 50+ geographies.
Understand how the market has been affected by the COVID-19 and how it is responding as the impact of the virus abates.
Assess the Russia - Ukraine war's impact on agriculture, energy and mineral commodity supply and its direct and indirect impact on the market.
Measure the impact of high global inflation on market growth.
Create regional and country strategies on the basis of local data and analysis.
Identify growth segments for investment.
Outperform competitors using forecast data and the drivers and trends shaping the market.
Understand customers based on the latest market shares.
Benchmark performance against key competitors.
Suitable for supporting your internal and external presentations with reliable high quality data and analysis
Report will be updated with the latest data and delivered to you within 3-5 working days of order along with an Excel data sheet for easy data extraction and analysis.
All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for poly adp-ribose polymerase (PARP) inhibitor? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The poly adp-ribose polymerase (PARP) inhibitor market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

The market characteristics section of the report defines and explains the market.
The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
The forecasts are made after considering the major factors currently impacting the market. These include:

The impact of sanctions, supply chain disruptions, and altered demand for goods and services due to the Russian Ukraine war, impacting various macro-economic factors and parameters in the Eastern European region and its subsequent effect on global markets.

The impact of higher inflation in many countries and the resulting spike in interest rates.

The continued but declining impact of COVID-19 on supply chains and consumption patterns.

Market segmentations break down the market into sub markets.
The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

Markets Covered:1) By Drug Type: Talazoparib; Veliparib; Olaparib; Other Drug Types
2) By Distribution Channel: Hospital Pharmacy; Online Pharmacy; Retail Pharmacy; Other Distribution Channels
3) By Application: Ovarian Cancer; Breast Cancer; Other Applications
4) By End Users: Hospitals; Homecare; Specialty Clinics; Other End Users
Companies Mentioned: Pfizer Inc.; Johnson & Johnson Services Inc.; AbbVie Inc.; Bayer AG; Novartis AG
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery format: PDF, Word and Excel Data Dashboard.

Product Code: r18203

1. Executive Summary

2. Poly ADP-Ribose Polymerase (PARP) Inhibitor Market Characteristics

3. Poly ADP-Ribose Polymerase (PARP) Inhibitor Market Trends And Strategies

4. Poly ADP-Ribose Polymerase (PARP) Inhibitor Market - Macro Economic Scenario

4.1. Impact Of High Inflation On The Market
4.2. Ukraine-Russia War Impact On The Market
4.3. COVID-19 Impact On The Market

5. Global Poly ADP-Ribose Polymerase (PARP) Inhibitor Market Size and Growth

5.1. Global Poly ADP-Ribose Polymerase (PARP) Inhibitor Market Drivers and Restraints
- 5.1.1. Drivers Of The Market
- 5.1.2. Restraints Of The Market
5.2. Global Poly ADP-Ribose Polymerase (PARP) Inhibitor Historic Market Size and Growth, 2018 - 2023, Value ($ Billion)
5.3. Global Poly ADP-Ribose Polymerase (PARP) Inhibitor Forecast Market Size and Growth, 2023 - 2028, 2033F, Value ($ Billion)

6. Poly ADP-Ribose Polymerase (PARP) Inhibitor Market Segmentation

6.1. Global Poly ADP-Ribose Polymerase (PARP) Inhibitor Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
Talazoparib
Veliparib
Olaparib
Other Drug Types
6.2. Global Poly ADP-Ribose Polymerase (PARP) Inhibitor Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
Hospital Pharmacy
Online Pharmacy
Retail Pharmacy
Other Distribution Channels
6.3. Global Poly ADP-Ribose Polymerase (PARP) Inhibitor Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
Ovarian Cancer
Breast Cancer
Other Applications
6.4. Global Poly ADP-Ribose Polymerase (PARP) Inhibitor Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
Hospitals
Homecare
Specialty Clinics
Other End Users

7. Poly ADP-Ribose Polymerase (PARP) Inhibitor Market Regional And Country Analysis

7.1. Global Poly ADP-Ribose Polymerase (PARP) Inhibitor Market, Split By Region, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
7.2. Global Poly ADP-Ribose Polymerase (PARP) Inhibitor Market, Split By Country, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

8. Asia-Pacific Poly ADP-Ribose Polymerase (PARP) Inhibitor Market

8.1. Asia-Pacific Poly ADP-Ribose Polymerase (PARP) Inhibitor Market Overview
Region Information, Impact Of COVID-19, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
8.2. Asia-Pacific Poly ADP-Ribose Polymerase (PARP) Inhibitor Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
8.3. Asia-Pacific Poly ADP-Ribose Polymerase (PARP) Inhibitor Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
8.4. Asia-Pacific Poly ADP-Ribose Polymerase (PARP) Inhibitor Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

9. China Poly ADP-Ribose Polymerase (PARP) Inhibitor Market

9.1. China Poly ADP-Ribose Polymerase (PARP) Inhibitor Market Overview
9.2. China Poly ADP-Ribose Polymerase (PARP) Inhibitor Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
9.3. China Poly ADP-Ribose Polymerase (PARP) Inhibitor Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
9.4. China Poly ADP-Ribose Polymerase (PARP) Inhibitor Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion

10. India Poly ADP-Ribose Polymerase (PARP) Inhibitor Market

10.1. India Poly ADP-Ribose Polymerase (PARP) Inhibitor Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
10.2. India Poly ADP-Ribose Polymerase (PARP) Inhibitor Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
10.3. India Poly ADP-Ribose Polymerase (PARP) Inhibitor Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

11. Japan Poly ADP-Ribose Polymerase (PARP) Inhibitor Market

11.1. Japan Poly ADP-Ribose Polymerase (PARP) Inhibitor Market Overview
11.2. Japan Poly ADP-Ribose Polymerase (PARP) Inhibitor Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
11.3. Japan Poly ADP-Ribose Polymerase (PARP) Inhibitor Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
11.4. Japan Poly ADP-Ribose Polymerase (PARP) Inhibitor Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

12. Australia Poly ADP-Ribose Polymerase (PARP) Inhibitor Market

12.1. Australia Poly ADP-Ribose Polymerase (PARP) Inhibitor Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
12.2. Australia Poly ADP-Ribose Polymerase (PARP) Inhibitor Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
12.3. Australia Poly ADP-Ribose Polymerase (PARP) Inhibitor Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

13. Indonesia Poly ADP-Ribose Polymerase (PARP) Inhibitor Market

13.1. Indonesia Poly ADP-Ribose Polymerase (PARP) Inhibitor Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
13.2. Indonesia Poly ADP-Ribose Polymerase (PARP) Inhibitor Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
13.3. Indonesia Poly ADP-Ribose Polymerase (PARP) Inhibitor Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

14. South Korea Poly ADP-Ribose Polymerase (PARP) Inhibitor Market

14.1. South Korea Poly ADP-Ribose Polymerase (PARP) Inhibitor Market Overview
14.2. South Korea Poly ADP-Ribose Polymerase (PARP) Inhibitor Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
14.3. South Korea Poly ADP-Ribose Polymerase (PARP) Inhibitor Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
14.4. South Korea Poly ADP-Ribose Polymerase (PARP) Inhibitor Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

15. Western Europe Poly ADP-Ribose Polymerase (PARP) Inhibitor Market

15.1. Western Europe Poly ADP-Ribose Polymerase (PARP) Inhibitor Market Overview
15.2. Western Europe Poly ADP-Ribose Polymerase (PARP) Inhibitor Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
15.3. Western Europe Poly ADP-Ribose Polymerase (PARP) Inhibitor Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
15.4. Western Europe Poly ADP-Ribose Polymerase (PARP) Inhibitor Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

16. UK Poly ADP-Ribose Polymerase (PARP) Inhibitor Market

16.1. UK Poly ADP-Ribose Polymerase (PARP) Inhibitor Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
16.2. UK Poly ADP-Ribose Polymerase (PARP) Inhibitor Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
16.3. UK Poly ADP-Ribose Polymerase (PARP) Inhibitor Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

17. Germany Poly ADP-Ribose Polymerase (PARP) Inhibitor Market

17.1. Germany Poly ADP-Ribose Polymerase (PARP) Inhibitor Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
17.2. Germany Poly ADP-Ribose Polymerase (PARP) Inhibitor Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
17.3. Germany Poly ADP-Ribose Polymerase (PARP) Inhibitor Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

18. France Poly ADP-Ribose Polymerase (PARP) Inhibitor Market

18.1. France Poly ADP-Ribose Polymerase (PARP) Inhibitor Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
18.2. France Poly ADP-Ribose Polymerase (PARP) Inhibitor Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
18.3. France Poly ADP-Ribose Polymerase (PARP) Inhibitor Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

19. Italy Poly ADP-Ribose Polymerase (PARP) Inhibitor Market

19.1. Italy Poly ADP-Ribose Polymerase (PARP) Inhibitor Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
19.2. Italy Poly ADP-Ribose Polymerase (PARP) Inhibitor Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
19.3. Italy Poly ADP-Ribose Polymerase (PARP) Inhibitor Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

20. Spain Poly ADP-Ribose Polymerase (PARP) Inhibitor Market

20.1. Spain Poly ADP-Ribose Polymerase (PARP) Inhibitor Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
20.2. Spain Poly ADP-Ribose Polymerase (PARP) Inhibitor Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
20.3. Spain Poly ADP-Ribose Polymerase (PARP) Inhibitor Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

21. Eastern Europe Poly ADP-Ribose Polymerase (PARP) Inhibitor Market

21.1. Eastern Europe Poly ADP-Ribose Polymerase (PARP) Inhibitor Market Overview
21.2. Eastern Europe Poly ADP-Ribose Polymerase (PARP) Inhibitor Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
21.3. Eastern Europe Poly ADP-Ribose Polymerase (PARP) Inhibitor Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
21.4. Eastern Europe Poly ADP-Ribose Polymerase (PARP) Inhibitor Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

22. Russia Poly ADP-Ribose Polymerase (PARP) Inhibitor Market

22.1. Russia Poly ADP-Ribose Polymerase (PARP) Inhibitor Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
22.2. Russia Poly ADP-Ribose Polymerase (PARP) Inhibitor Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
22.3. Russia Poly ADP-Ribose Polymerase (PARP) Inhibitor Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

23. North America Poly ADP-Ribose Polymerase (PARP) Inhibitor Market

23.1. North America Poly ADP-Ribose Polymerase (PARP) Inhibitor Market Overview
23.2. North America Poly ADP-Ribose Polymerase (PARP) Inhibitor Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
23.3. North America Poly ADP-Ribose Polymerase (PARP) Inhibitor Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
23.4. North America Poly ADP-Ribose Polymerase (PARP) Inhibitor Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

24. USA Poly ADP-Ribose Polymerase (PARP) Inhibitor Market

24.1. USA Poly ADP-Ribose Polymerase (PARP) Inhibitor Market Overview
24.2. USA Poly ADP-Ribose Polymerase (PARP) Inhibitor Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
24.3. USA Poly ADP-Ribose Polymerase (PARP) Inhibitor Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
24.4. USA Poly ADP-Ribose Polymerase (PARP) Inhibitor Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

25. Canada Poly ADP-Ribose Polymerase (PARP) Inhibitor Market

25.1. Canada Poly ADP-Ribose Polymerase (PARP) Inhibitor Market Overview
25.2. Canada Poly ADP-Ribose Polymerase (PARP) Inhibitor Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
25.3. Canada Poly ADP-Ribose Polymerase (PARP) Inhibitor Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
25.4. Canada Poly ADP-Ribose Polymerase (PARP) Inhibitor Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

26. South America Poly ADP-Ribose Polymerase (PARP) Inhibitor Market

26.1. South America Poly ADP-Ribose Polymerase (PARP) Inhibitor Market Overview
26.2. South America Poly ADP-Ribose Polymerase (PARP) Inhibitor Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
26.3. South America Poly ADP-Ribose Polymerase (PARP) Inhibitor Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
26.4. South America Poly ADP-Ribose Polymerase (PARP) Inhibitor Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

27. Brazil Poly ADP-Ribose Polymerase (PARP) Inhibitor Market

27.1. Brazil Poly ADP-Ribose Polymerase (PARP) Inhibitor Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
27.2. Brazil Poly ADP-Ribose Polymerase (PARP) Inhibitor Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
27.3. Brazil Poly ADP-Ribose Polymerase (PARP) Inhibitor Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

28. Middle East Poly ADP-Ribose Polymerase (PARP) Inhibitor Market

28.1. Middle East Poly ADP-Ribose Polymerase (PARP) Inhibitor Market Overview
28.2. Middle East Poly ADP-Ribose Polymerase (PARP) Inhibitor Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
28.3. Middle East Poly ADP-Ribose Polymerase (PARP) Inhibitor Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
28.4. Middle East Poly ADP-Ribose Polymerase (PARP) Inhibitor Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

29. Africa Poly ADP-Ribose Polymerase (PARP) Inhibitor Market

29.1. Africa Poly ADP-Ribose Polymerase (PARP) Inhibitor Market Overview
29.2. Africa Poly ADP-Ribose Polymerase (PARP) Inhibitor Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
29.3. Africa Poly ADP-Ribose Polymerase (PARP) Inhibitor Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
29.4. Africa Poly ADP-Ribose Polymerase (PARP) Inhibitor Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

30. Poly ADP-Ribose Polymerase (PARP) Inhibitor Market Competitive Landscape And Company Profiles

30.1. Poly ADP-Ribose Polymerase (PARP) Inhibitor Market Competitive Landscape
30.2. Poly ADP-Ribose Polymerase (PARP) Inhibitor Market Company Profiles
- 30.2.1. Pfizer Inc.
  - 30.2.1.1. Overview
  - 30.2.1.2. Products and Services
  - 30.2.1.3. Strategy
  - 30.2.1.4. Financial Performance
- 30.2.2. Johnson & Johnson Services Inc.
  - 30.2.2.1. Overview
  - 30.2.2.2. Products and Services
  - 30.2.2.3. Strategy
  - 30.2.2.4. Financial Performance
- 30.2.3. AbbVie Inc.
  - 30.2.3.1. Overview
  - 30.2.3.2. Products and Services
  - 30.2.3.3. Strategy
  - 30.2.3.4. Financial Performance
- 30.2.4. Bayer AG
  - 30.2.4.1. Overview
  - 30.2.4.2. Products and Services
  - 30.2.4.3. Strategy
  - 30.2.4.4. Financial Performance
- 30.2.5. Novartis AG
  - 30.2.5.1. Overview
  - 30.2.5.2. Products and Services
  - 30.2.5.3. Strategy
  - 30.2.5.4. Financial Performance

31. Poly ADP-Ribose Polymerase (PARP) Inhibitor Market Other Major And Innovative Companies

31.1. Sanofi S.A.
31.2. AstraZeneca plc
31.3. GlaxoSmithKline plc.
31.4. Takeda Pharmaceutical Company Limited
31.5. Merck KGaA
31.6. Teva Pharmaceutical Industries Ltd.
31.7. Daiichi Sankyo Company Limited
31.8. Eisai Co. Ltd.
31.9. Ipsen Biopharmaceuticals Inc.
31.10. Genentech Inc.
31.11. BioMarin Pharmaceutical Inc.
31.12. Seattle Genetics Inc.
31.13. Medivation Inc.
31.14. Myriad Genetics Inc.
31.15. PharmaMar S.A.

32. Global Poly ADP-Ribose Polymerase (PARP) Inhibitor Market Competitive Benchmarking

33. Global Poly ADP-Ribose Polymerase (PARP) Inhibitor Market Competitive Dashboard

34. Key Mergers And Acquisitions In The Poly ADP-Ribose Polymerase (PARP) Inhibitor Market

35. Poly ADP-Ribose Polymerase (PARP) Inhibitor Market Future Outlook and Potential Analysis

35.1 Poly ADP-Ribose Polymerase (PARP) Inhibitor Market In 2028 - Countries Offering Most New Opportunities
35.2 Poly ADP-Ribose Polymerase (PARP) Inhibitor Market In 2028 - Segments Offering Most New Opportunities
35.3 Poly ADP-Ribose Polymerase (PARP) Inhibitor Market In 2028 - Growth Strategies
- 35.3.1 Market Trend Based Strategies
- 35.3.2 Competitor Strategies

36. Appendix

36.1. Abbreviations
36.2. Currencies
36.3. Historic And Forecast Inflation Rates
36.4. Research Inquiries
36.5. The Business Research Company
36.6. Copyright And Disclaimer